BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 10, 2011
View Archived Issues
Sirukumab is safe in patients with rheumatoid arthritis, cutaneous and systemic lupus erythematosus
Read More
Galapagos discloses first-in-human data on GLPG-0634
Read More
OSI claims new inhibitors of insulin-like growth factor 1 receptor and/or insulin receptor
Read More
Eli Lilly describes new opioid NOP receptor antagonists
Read More
New lysophospholipid S1P1 receptor agonists presented by Receptos
Read More
Orchid Chemicals & Pharmaceuticals synthesizes new histone deacetylase inhibitors
Read More
Novel arylpiperazine-containing purine derivatives patented by Green Cross for depression
Read More
Merck & Co. changes prescribing information for simvastatin following FDA review of myopathy risk
Read More
Pharmasset expands treatment cohorts in trial of PSI-7977 in chronic hepatitis C
Read More
Anavex Life Sciences initiates scale-up manufacturing of lead compound ANAVEX 1-41
Read More
Seattle Genetics exercises option to codevelop second antibody-drug conjugate with Agensys
Read More
MK-2048 is a candidate therapy for adult T-cell leukemia / News in Context
Read More
Phase I trial assesses safety and tolerability of KW-2450 in pretreated advanced solid tumors
Read More
Intercell and Merck & Co. provide product updates
Read More
GQ-16 may provide safe PPAR-gamma activation for diabetes treatment
Read More
Merck Serono and Affectis sign agreement to develop oral P2X7 receptor antagonists
Read More
Galapagos' GLPG-0634 enters phase II trial in rheumatoid arthritis
Read More
Avila Therapeutics and NIAID enter agreement for preclinical evaluation of AVL-192
Read More
AVI BioPharma to revise protocol of phase II eteplirsen trial in Duchenne's muscular dystrophy
Read More
Telik initiates phase II trial of Telintra in lenalidomide-refractory or -resistant del 5q MDS
Read More
Marina Biotech completes dosing of first cohort in phase Ib/IIa CEQ-508 trial in FAP
Read More
Enrollment complete in pivotal phase III CENTRIC trial
Read More
Drug safety monitoring board recommends advancing DIGNITY to phase II
Read More
Benefits sustained at 18 months in APOLLO trial of cardiac cell therapy after heart attack
Read More
Xgeva approved in Canada to reduce risk of skeletal-related events due to certain bone metastases
Read More